Centessa Pharmaceuticals (NASDAQ:CNTA) Trading Up 4.2%

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) shot up 4.2% during trading on Friday . The company traded as high as $16.70 and last traded at $16.52. 125,493 shares were traded during trading, a decline of 68% from the average session volume of 386,714 shares. The stock had previously closed at $15.85.

Analysts Set New Price Targets

Several research analysts have recently weighed in on CNTA shares. Jefferies Financial Group lifted their price target on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Guggenheim raised their price objective on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. BMO Capital Markets increased their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday. Oppenheimer restated an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Finally, B. Riley started coverage on Centessa Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $33.00 price target for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $25.17.

Centessa Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 0.27, a quick ratio of 13.29 and a current ratio of 13.29. The business’s fifty day moving average price is $12.15 and its two-hundred day moving average price is $10.60. The stock has a market capitalization of $1.68 billion, a P/E ratio of -11.74 and a beta of 1.44.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). As a group, sell-side analysts forecast that Centessa Pharmaceuticals plc will post -1.61 earnings per share for the current year.

Insider Activity

In related news, CEO Saurabh Saha sold 4,169 shares of Centessa Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total transaction of $51,362.08. Following the completion of the transaction, the chief executive officer now directly owns 827,755 shares of the company’s stock, valued at approximately $10,197,941.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, insider Gregory M. Weinhoff sold 12,198 shares of the company’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $12.17, for a total transaction of $148,449.66. Following the completion of the sale, the insider now directly owns 241,171 shares in the company, valued at approximately $2,935,051.07. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Saurabh Saha sold 4,169 shares of Centessa Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total value of $51,362.08. Following the completion of the transaction, the chief executive officer now owns 827,755 shares in the company, valued at approximately $10,197,941.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 216,873 shares of company stock valued at $3,472,000. 11.59% of the stock is currently owned by company insiders.

Institutional Trading of Centessa Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Quarry LP purchased a new stake in shares of Centessa Pharmaceuticals during the 4th quarter valued at $48,000. EntryPoint Capital LLC acquired a new position in shares of Centessa Pharmaceuticals in the first quarter valued at about $109,000. Sandia Investment Management LP purchased a new position in Centessa Pharmaceuticals during the 2nd quarter worth approximately $90,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Centessa Pharmaceuticals by 69.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 10,817 shares of the company’s stock worth $122,000 after purchasing an additional 4,423 shares during the last quarter. Finally, Fred Alger Management LLC purchased a new stake in Centessa Pharmaceuticals in the second quarter valued at $99,000. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.